Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics (NKTR), has demonstrated a consistent pattern of selling company shares over the past two years, with no recorded purchases in SEC filings. Since February 2024, Zalevsky has executed 15 sales totaling approximately $397,938, with transactions ranging from modest dispositions like $6,129 on February 20, 2024, to larger sales such as $137,936 on January 20, 2026. The activity intensified in late 2025 and early 2026, with multiple sales clustered in September 2025 (four transactions totaling $57,792) and a significant $137,936 sale in January 2026 followed by an additional $13,140 disposition in February 2026.
Notably, Zalevsky’s filings include several awards of securities (coded "A") with zero reported value, likely representing equity grants or option exercises that did not involve open-market purchases. The absence of buy transactions and the repeated sales—particularly the higher-value dispositions in late 2025 and early 2026—suggest a directional reduction in his NKTR holdings. All transactions involve Nektar Therapeutics, indicating his trading activity remains concentrated in his employer’s stock. The pattern aligns with a net divestment approach, though the sales represent a mix of smaller routine disposals and occasional larger transactions. No material buy-side activity offsets the steady outflow.
AI-assisted summary